RENO, NV - (NewMediaWire) - July 07, 2015 - Lifeline (OTC PINK: LLBO) and Cyrcadia, Inc. ("Cyrcadia") announce that Cyrcadia has commenced a clinical trial for its wearable early detection of breast cancer device and is enrolling the first trial participants at El Camino Hospital, in Mountain View, California. Utilizing its previous FDA cleared device as a predicate, Cyrcadia is combining its fourth generation, wearable device technology, made by Flextronics, and the Salesforce database software to track the clinical trial results.

About El Camino Hospital

El Camino Hospital is an acute-care, 443-bed, nonprofit and locally governed organization with campuses in Mountain View and Los Gatos, Calif. In addition to cancer care, key medical specialties include behavioral health, heart and vascular, men's health, neuroscience, orthopedic and spine, senior health, urology, and the first Women's Hospital in Northern California. The hospital is recognized as a national leader in the use of health information technology and wireless communications, and has been awarded the Gold Seal of Approval from The Joint Commission as a Primary Stroke Center, as well as back-to-back ANCC Magnet Recognitions for Nursing Care.

About Cyrcadia Health

Cyrcadia Health, founded as First Warning Systems in 2008, is based in Reno, Nev. The company's product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the product. Cyrcadia Health technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc. (OTC PINK: LLBO). The company is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets, with FDA applications following for the US market. Visit Cyrcadia Health at www.cyrcadiahealth.com.

About Lifeline Biotechnologies, Inc. 

In 2008, Lifeline Biotechnologies founded Cyrcadia, Inc. The main purpose of founding Cyrcadia was to establish a better value of its technology and to obtain financing at more favorable rates. LLBO's primary asset is its investment in Cyrcadia, Inc. and is its largest single shareholder. LLBO also has a five percent (5%) royalty based on all Cyrcadia product sales. Lifeline conducted three rounds of proof of concept trials, the results were validated by the Aero Space Engineers at Nangyang Technological University, Singapore. Nanyang's Aero Space Engineers are recognized world leaders in "Pattern Recognition," which is the basis of Lifeline's technology. Lifeline owns all of the issued software patents which are licensed to Cyrcadia.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions

Lifeline Biotech (CE) (USOTC:LLBO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Lifeline Biotech (CE) (USOTC:LLBO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024